Merck Collaborates with Caris Life Sciences to Develop First-in-Class Antibody-Drug Conjugates
German pharmaceutical giant Merck (ETR: MRK) has entered into a strategic collaboration with Caris Life...
Merck
Merck Expands Global Footprint with Largest M Lab Collaboration Center in Shanghai
Merck KGaA (ETR: MRK), a leading German technology company, has announced the completion of the...
MSD’s Winrevair Approved by FDA as First Activin Signaling Inhibitor for Pulmonary Arterial Hypertension
The US Food and Drug Administration (FDA) has granted Merck, Sharp & Dohme (MSD; NYSE:...
MSD’s Phase III Trial of Keytruda Plus Lynparza Misses Primary Endpoints in NSCLC
Merck, Sharp & Dohme (MSD; NYSE: MRK) has announced an unfavorable outcome for a Phase...
MSD Strikes Deal with Pearl Bio to Tap into Synthetic Biology for Oncology Targets
Merck, Sharp & Dohme (MSD; NYSE: MRK) has entered into a strategic agreement with Pearl...
MSD Partners with IDEAYA Biosciences to Develop Combination Therapy for Endometrial Cancer
Merck, Sharp & Dohme (MSD; NYSE: MRK) has announced a partnership with IDEAYA Biosciences (NASDAQ:...
Merck’s 2023 Annual Report: A Mixed Bag Amid Global Challenges
Merck KGaA (ETR: MRK), a leading German chemical, reported a 5.6% decline in its global...
Gilead and MSD Report Positive Interim Data for Once-Weekly HIV Treatment in Phase II Trial
Gilead Sciences Inc. (NASDAQ: GILD) and Merck & Co., Inc., known as MSD (NYSE: MRK),...
Merck Teams Up with C4 Therapeutics for Targeted Protein Degraders in Oncology
Merck (NYSE: MRK), a Germany-headquartered science and technology company, has entered into a partnership with...
Merck’s Mavenclad Demonstrates Lasting Efficacy in RMS Patients, New Data Show
Merck KGaA (ETR: MRK), a German multinational pharmaceutical, chemical, and life sciences company, has this...
Kelun-Biotech Launches Clinical Trials for SKB264, Triggering $75 Million Milestone Payment from MSD
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (HKG: 6990) has announced the initiation of clinical trials for...
MSD’s Belzutifan and Sperogenix’s Vamorolone Targeted for Priority Review by China’s CDE
The Center for Drug Evaluation (CDE) website has indicated that Merck, Sharp & Dohme’s (MSD;...
Merck’s Keytruda Under Priority Review for New Indication in Endometrial Carcinoma
This week, the U.S. FDA granted priority review status to an indication extension filing from...
German Tech Giant Merck Launches Digital Hub in Singapore to Boost Healthcare and Semiconductor Research
Merck KGaA (ETR: MRK), a leading German technology company, last week inaugurated a digital hub...
Merck KGaA’s Tepmetko Launches in China, Expanding Access to MET Inhibitor for Lung Cancer Patients
Merck KGaA (NYSE: MRK), a leading German science and technology company, has announced the commercial...
Merck Q4 Sales Grow 6% YOY, Driven by Pharmaceutical Segment and HPV Vaccine Demand
Merck, Sharp & Dohme (MSD; NYSE: MRK), a leading US pharmaceutical company, has released its...
MSD Partners with Variational AI to Harness Generative AI for Drug Discovery
Merck, Sharp & Dohme (MSD; NYSE: MRK) has embarked on a collaborative project with Canadian...
BJ Bioscience Inc. Faces Bankruptcy as Hangzhou Court Accepts Liquidation Application
The Hangzhou Yuhang District People’s Court has released a document indicating that BJ Bioscience Inc.’s...
MSD’s Keytruda Combines with PharmAbcine’s PMC-309 in Phase Ia/b Solid Tumor Trial
Merck, Sharp & Dohme (MSD; NYSE: MRK) has announced that its blockbuster anti-PD-1 drug Keytruda...
Merck’s Bavencio Shows Promising Survival Data in Real-World Urothelial Carcinoma Studies
German pharmaceutical company Merck (NYSE: MRK) has released data from real-world studies for its anti-PD-L1...